Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study
Related Experiment Videos
Kwang Kon Koh1, Ji Won Son, Jeong Yeal Ahn
1kVascular Medicine and Atherosclerosis Unit, Cardiology, Gil Heart Center, Gachon Medical School, Kuwol-dong 1198, Namdong-gu, Incheon 405-760, Korea. kwangk@ghil.com
Insights
Statin (simvastatin) and ACE inhibitor (ramipril) therapies improved endothelial function in patients with coronary artery disease. Combination therapy showed greater, though not always significant, benefits compared to statin alone.
Area of Science:
- Cardiovascular Pharmacology
- Endothelial Function Research
- Lipid Metabolism Studies
Background:
- Coronary artery disease (CAD) and hypercholesterolemia are significant cardiovascular risk factors.
- Statin and angiotensin-converting enzyme (ACE) inhibitor therapies have distinct mechanisms impacting vascular health.
- Understanding their combined effects on vascular function in CAD patients is crucial.
Purpose of the Study:
- To investigate the vascular responses to simvastatin and ramipril in hypercholesterolemic patients with CAD.
- To compare the efficacy of monotherapy versus combination therapy on endothelial function and inflammatory markers.
- To assess the differential biological effects of statins and ACE inhibitors in this patient population.
Main Methods:
- Randomized, double-blind, placebo-controlled, crossover study design.
- 32 hypercholesterolemic patients with CAD received simvastatin (20 mg) or ramipril (10 mg) daily for 2 months, followed by a 2-month washout period.
- Vascular responses, including flow-mediated dilation, and plasma levels of nitrate, MDA, MCP-1, CRP, and PAI-1 antigen were measured.
Main Results:
- Both simvastatin alone and in combination with ramipril significantly improved flow-mediated dilation and reduced MDA and MCP-1 levels.
- Combination therapy demonstrated a trend towards greater improvement in flow-mediated dilation and reduction in certain markers compared to simvastatin alone, but differences were not always statistically significant.
- Simvastatin alone or combined with ramipril significantly altered lipoproteins and showed beneficial effects on endothelial function.
Conclusions:
- Simvastatin and ramipril monotherapies, as well as their combination, exert significant beneficial effects on endothelial function in hypercholesterolemic patients with CAD.
- While combination therapy may offer additive benefits, the incremental advantage over statin monotherapy was not consistently statistically significant for all measured parameters.
- Further research may be warranted to elucidate the optimal therapeutic strategies for managing vascular dysfunction in CAD.
Abstract:
Because the mechanisms of the biological effects of statin and angiotensin converting enzyme inhibitor therapies differ, we studied the vascular responses to these therapies in hypercholesterolemic patients with coronary artery disease. We administered simvastatin 20 mg and placebo or ramipril 10 mg daily during 2 months with washout 2 months to 32 hypercholesterolemic patients with coronary artery disease. This study was randomized, double-blind, placebo-controlled, crossover in design. Simvastatin alone or combined with ramipril significantly changed lipoproteins, and improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements by 33 +/- 6% and by 50 +/- 14%, respectively (both P <0.001) and reduced plasma levels of nitrate relative to baseline measurements (P=0.413 and 0.037, respectively), the plasma MDA levels relative to baseline measurements by 8 +/- 8% and by 18 +/- 9% (P=0.039 and P <0.001, respectively) and MCP-1 relative to baseline measurements by 7 +/- 4% and by 13 +/- 3%, respectively (P=0.019 and P <0.001, respectively), and CRP from 0.22 to 0.14 mg/dl and from 0.22 to 0.15 mg/dl, respectively (P=0.124 and 0.002, respectively), and PAI-1 antigen relative to baseline measurements (P=0.690 and 0.018, respectively). However, simvastatin combined with ramipril changed to greater but statistically insignificant extent the percent flow-mediated dilator response to hyperemia and plasma levels of nitrate, MDA, MCP-1, and PAI-1 antigen than simvastatin alone. Simvastatin alone or combined with ramipril showed significant beneficial effects on endothelial function in hypercholesterolemic patients with coronary artery disease. However, simvastatin combined with ramipril did not significantly change, compared with simvastatin alone.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Antihypertensive Drugs: Vasodilators
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Acute Coronary Syndrome III: Diagnostic Studies